<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5376">
  <stage>Registered</stage>
  <submitdate>22/04/2015</submitdate>
  <approvaldate>22/04/2015</approvaldate>
  <nctid>NCT02435680</nctid>
  <trial_identification>
    <studytitle>Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)</studytitle>
    <scientifictitle>A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)</scientifictitle>
    <utrn />
    <trialacronym>TNBC</trialacronym>
    <secondaryid>2015-000179-29</secondaryid>
    <secondaryid>CMCS110Z2201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Triple Negative Breast Cancer (TNBC) With High TAMs</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MCS110
Treatment: drugs - carboplatin
Treatment: drugs - gemcitabine

Experimental: Arm 1: MCS110+carboplatin+gemcitabine - MCS110+carboplatin+gemcitabine

Active Comparator: Arm 2: carboplatin+gemcitabine - carboplatin+gemcitabine


Treatment: drugs: MCS110
taken by I.V

Treatment: drugs: carboplatin
taken by I.V

Treatment: drugs: gemcitabine
taken by I.V

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival (PFS) as per RECIST v1.1 (by local investigator assessment)</outcome>
      <timepoint>7 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with adverse events and serioaus adverse events</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration of free MCS110 and derived Pharmacokinetics (PK) parameters: AUC</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration of free MCS110 and derived Pharmacokinetics (PK) parameters: Cmax</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of carboplatin, gemcitabine and 2',2'-difluoro-deoxyuridine (dFdU)</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Colony stimulation factor -1 (CSF-I) circulating levels, serum C-terminal telopeptide of type I collagen (CTX-I) and circulating monocytes</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor associated macrophage (TAM) and Tumor infiltrating lymphocyte (TIL) content in pre- and post-dose tumor biopsies</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor response per RECIST v1.1 (by local investigator assessment)</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult women (= 18 years of age) with advanced TNBC.

          -  Histological or cytological evidence of estrogen-receptor negative (ER-), progesterone
             receptor negative (PgR-) and human epidermal growth factor-2 receptor negative (HER2-)
             Breast Cancer by local laboratory testing, based on last available tumor tissue.

          -  ER/PgR negativity to follow local guidelines

          -  If IHC HER2 2+, a negative FISH test is required

          -  A pre-treatment tumor biopsy demonstrating high TAM content as assessed per the
             central laboratory

          -  Patients must have:

        At least one measurable lesion per RECIST 1.1. (Note: Measurable lesions include lytic or
        mixed (lytic + blastic) bone lesions, with an identifiable soft tissue component that meets
        the measurability criteria)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior chemotherapy for advanced BC. Previous adjuvant/neoadjuvant chemotherapy is
             allowed (carboplatin, cisplatin or gemcitabine only if &gt; 12 months has passed since
             last administration).

          -  Therapy for underlying malignancy within 2 weeks prior to start of study treatment:

          -  Chemotherapy, biologic therapy (antibodies and biologically targeted small molecules)

          -  Radiotherapy

          -  Major surgery

          -  Patients receiving concomitant immunosuppressive agents or chronic corticosteroids
             (=10 mg of prednisone or equivalent) at the time of first study dose.

          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             screening.

          -  Known history of human immunodeficiency virus or active infection with hepatitis virus
             or any uncontrolled active systemic infection.

          -  Patients with the following laboratory values during screening and on Day 1 predose:

          -  Absolute Neutrophil Count (ANC) &lt; 1.5x109/L

          -  Hemoglobin &lt; 9 g/dL

          -  Platelets &lt; 100x109/L

          -  Serum creatinine &gt; 1.5 x ULN

          -  Serum total bilirubin &gt; 1.5 x ULN

          -  AST/SGOT and ALT/SGPT &gt; 3.0 x ULN</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>10/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Novartis Investigative Site - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Czech republic</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Herblain CÃ©dex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong SAR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and
      gemcitabine (carbo/gem) in advanced TNBC patients</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02435680</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>